Background
==========

Recent statistics show high morbidity and mortality rates due to thoracic aortic dissection (TAD) \[[@b1-medscimonit-25-2419],[@b2-medscimonit-25-2419]\]. A mortality rate of up to 50% or more within 48 hours has been reported for untreated TAD, and this rate increases 1% to 2% per hour. When it is not diagnosed, ascending aortic dissection has a 3-month mortality rate of up to 90% \[[@b3-medscimonit-25-2419]\]. Due to its many complications, the morbidity and mortality rates of TAD remain high notwithstanding the recent tremendous advancements in diagnostic and therapeutic approaches for this disease. Therefore, is it necessary to identify what may lead to TAD. The etiology of TAD is complex and heterogeneous, and previous studies clearly showed that in addition to environmental risk factors, genetic factors may also determine susceptibly to the disease. As a consequence, investigating the TAD-related pathogenic genes would be beneficial to understand the etiology of TAD and to prevent and treat the disease.

Hypertension is thought to be a key determinant of TAD development. Indeed, a history of hypertension is often reported in up to 75% of acute Stanford type A aortic dissection patients. It can cause hemodynamic changes in the aortic cavity, leading to stress changes in the vessel wall. Moreover, the weakening and destruction of the aortic wall is known to be influenced by hypertension, leading to TAD. Arteries are mainly composed of the vascular smooth muscle. In previous reports, vascular smooth muscle cells (VSMCs) were found to be closely related to multiple aortic diseases \[[@b4-medscimonit-25-2419]\]. Furthermore, some studies have shown that abnormal hemodynamics and hormone levels can lead to VSMC dysfunction in some cases and result in decreased proliferation and migration abilities \[[@b4-medscimonit-25-2419]--[@b6-medscimonit-25-2419]\]. In this process, the aortic wall is ultimately thinned \[[@b7-medscimonit-25-2419]\], which is considered the pathologic basis of aortic dissection.

Mitofusion-2 (Mfn2), is a recently identified gene that is localized to chromosome 1p36.22. Spanning 4.16 kb of genomic DNA, the gene encodes a protein containing 661 amino acids. The expression of Mfn2 produces a protein found on the mitochondrial membrane which participates in processes such as regulating mitochondrial networks and fusion \[[@b8-medscimonit-25-2419]\]. Inadequate regulation of mitochondrial fusion and fission results in a series of problems such as apoptosis disorders and energy metabolic dysfunctions \[[@b9-medscimonit-25-2419]\]. During the proliferation of VSMCs, Mfn2 is a negative phase regulatory factor in the signaling pathway of extracellular single-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) \[[@b8-medscimonit-25-2419],[@b10-medscimonit-25-2419]\]. Notably, several studies have shown that Mfn2 gene polymorphisms are predicts the risk of essential hypertension in the Han Chinese population \[[@b11-medscimonit-25-2419]--[@b13-medscimonit-25-2419]\]. Therefore, we inferred that Mfn2 may be associated with the risk of TAD as no study has examined this relationship. Thus, the relationship between Mfn2 and the risk of TAD in a Han Chinese population was herein studied.

Material and Methods
====================

Patients
--------

This study was approved by the ethics committee of Beijing Anzhen Hospital of Capital Medical University. Signed written informed consents were obtained from all participants before the study. We assigned all participants into 2 categories: the control group and TAD group. All participants were of Han Chinese ancestry without intermarriages. Participants were enrolled at the Beijing Anzhen Hospital of Capital Medical University, Beijing, China. TAD was diagnosed on the basis of computed tomography angiography (CTA) and other imaging examinations according to the new guidelines for TAD diagnosis \[[@b14-medscimonit-25-2419]\]. These guidelines have been recommended by several academic authorities, including the American Heart Association. There were several exclusion criteria, including familial aortic dissection, i.e., one or more family members had TAD; Ehlers-Danlos, Marfan, and Loeys-Dietz syndromes, and other genetic defect syndromes; aortic arch constriction, aortic wall hematoma, and other aortic diseases; diabetes mellitus; primary kidney disease; endocrine or cancers disease. Furthermore, control participants were required to undergo at least one imaging examination, such as aortic CTA, MRI, echocardiography or aortic imaging, to make a clear diagnosis excluding TAD and other related diseases. Individuals in the TAD group and control group were not family members.

An individual with a mean diastolic blood pressure (DBP) ≥90 mmHg and/or a mean systolic blood pressure (SBP) ≥140 mmHg was considered hypertensive. In addition, patients who regularly used antihypertensive medicine were considered hypertensive. SBP and DBP were measured at the first and fifth Korotkoff sounds, respectively. Data relating to drinking and smoking habits were recorded during the interview. Those who smoked \>100 cigarettes were designated as smokers, while those who drank \>12 times in a year were designated as drinkers \[[@b15-medscimonit-25-2419],[@b16-medscimonit-25-2419]\]. Our study was performed in compliance with the Declaration of Helsinki, and all participants signed an informed consent form. Appropriate permission was granted by the Ethics Committee of our hospital.

Genotyping and identification of SNP
------------------------------------

We chose common single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) \>0.10 in Mfn2 in the Han Chinese population dataset from the International HapMap Project SNP database (*<http://www.hapmap.org/>*. We selected the tag SNPs, meaning the remaining common SNPs with an r^2^ ≥ 0.85, by Haploview 4.2 software (*<http://www.broad.mit.edu/mpg/haploview>*). Based on these criteria, we selected 6 tag SNPs of Mfn2 (rs2236057, rs17037564, rs2295281, rs3766741, rs2236058, and rs2336384).

We used ethylene diamine tetra-acetic acid (EDTA)-anticoagulated vacutainer tubes to collect blood samples. Using the common phenol-chloroform method, we isolated genomic DNA from peripheral blood leukocytes, which were kept at −80°C. TaqMan assays were then performed using the selected SNPs. The probes and primers used for SNP genotyping for rs2295281 C\_\_16189654_10, rs2236058C\_\_15953634_10, rs2236057C\_\_15953633_10, rs2336384 C\_\_11461995_10, rs3766741C\_\_25606040_10, and rs17037564 C\_\_32800152_10 were purchased from Applied Biosystems Assay (Foster City, CA, USA). The assay reactions contained TaqMan EXPress Master Mix (2×), working stock of SNP Genotyping Assay (20×) and genomic DNA in a final volume of 5 μL. We used a GeneAmpR PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) for amplification, and the reaction protocol was as follows: initial denaturation and activation at 95°C for 1 minute, followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. A negative control well was included in each 384-well plate which carried 2 samples without DNA and 2 duplicate samples (control). The plates were scanned using an ABI HT 7900 machine, and the Allelic Discrimination of SDS 2.0 was used for the end-point analysis. All the operators were trained professionally.

Statistical analysis
--------------------

Statistical Product and Service Solutions (SPSS) (Version 21.0) (IBM, Armonk, NY, USA) was applied for data analysis. Data with normal distribution is shown as mean ± standard deviation and that with non-normal distribution is shown as median (25^th^/75^th^ quartiles). Categorized data are presented as percentages. Data from different groups were compared using the chi-square test, Student's *t*-test, and the Mann-Whitney U test. All analyses were 2-tailed, and *P*\<0.05 was defined as indicating statistical significance. Hardy-Weinberg equilibrium (HWE) was performed as previously reported \[[@b17-medscimonit-25-2419]\]. The chi-square test was used to compare the allelic and genotypic frequencies between the TAD group and the control group. Logistic regression analysis was applied to explore the relationship between each Mfn2 SNP and TAD risk under different genetic models (recessive, dominant, and additive models) subsequent to adjustment for confounding factors. Furthermore, we calculated the 95% confidence intervals (95% CIs) and odds ratios (ORs).

Results
=======

Characteristics of the participants
-----------------------------------

The number of participants included in this study was 200 TAD cases (45 females and 155 males; mean age 47.33±10.81) and 451 controls (173 females and 278 males; mean age 47.94±5.54). [Table 1](#t1-medscimonit-25-2419){ref-type="table"} shows the clinical data of all participants. All participants in the control group and the TAD group were age-matched. Among all the individuals, we found that SBP, urea nitrogen (UREA), creatinine (CREA), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), and total cholesterol (TCHO) were remarkably higher in TAD patients relative to the controls. Hypertension and smoking were found to be remarkably higher in total TAD participants relative to the control group. The following parameters were not significantly different between the control and the TAD participants: body mass index (BMI), age, and DBP. The incidence of drinking was lower in the control group relative to the TAD group.

Distribution and detection of SNPs
----------------------------------

A total of 6 SNPs with a MAF \>0.10 in Mfn2 were selected as the tag SNPs of the gene, and Mfn2 was genotyped in all participants in strict accordance with the methodical steps described. Among all participants, 100.0% of the rs2295281 samples, 98.8% of the rs2236058 samples, 98.6% of the rs2336384 samples, 99.7% of the rs3766741 samples, and 99.5% of the rs17037564 samples were successfully genotyped. No variants of rs2236057 were detected in the TAD group.

The genotype frequencies for all 5 SNPs were in line with HWE in the control group (rs2336384, *P*=0.318, *F*=0.047; rs2295281, *P*=0.249, *F*=0.054; rs17037564, *P*=0.059, *F*=0.096; rs2236058, *P*=0.096, *F*=0.079; rs3766741, *P*=0.203, *F*=0.060), indicating that the results of this study have a representative genetic group. The genotype distribution and allele frequency of each locus are shown in [Tables 2](#t2-medscimonit-25-2419){ref-type="table"} and [3](#t3-medscimonit-25-2419){ref-type="table"}, respectively. Univariate analysis showed that the genotype distribution of rs2295281 and rs2236058 differed significantly between the TAD group and control group (*P*\<0.05). These findings indicated that these 2 sites might be linked to the risk of TAD. But rs2336384, rs17037564, or rs3766741 were not associated with the risk of TAD.

Because we found that polymorphisms of Mfn2 were associated with hypertension in a previous study, we performed subgroup analysis according to whether patients had hypertension. Univariate analysis indicated that the genotype distribution of rs2295281 in the hypertension subgroup was remarkably linked to TAD risk (*P*=0.046). In the normotensive subgroup, the locus and the risk of aortic dissection were not correlated. These results indicated a significant effect of the interaction between this polymorphism and hypertension on TAD. The genotype distribution and allele frequency of the rs2236058 (*P*=0.007) locus were strongly correlated with TAD in the normotensive subgroup, and CG genotype and CC genotype (*P*=0.034) may be at higher risk of developing aortic dissection. This locus was not found to be associated with TAD in the hypertension subgroup.

Association analyses
--------------------

Because the effects of genes on the phenotype of a disease usually follow a certain genetic pattern, such as additive genetic models, dominant genetic models, recessive genetic models, or homozygous models, we analyzed the correlation between different polymorphic *loci* of Mfn2 and the susceptibility to TAD. To exclude the effects of possible confounding factors on the correlation analysis of gene mutation sites with TAD, we used logistic regression to correct the following factors to prevent bias, including sex, age, BMI, hypertension history, TCHO, triglyceride, drinking, and smoking. The outcomes from the regression analysis are shown in [Tables 4](#t4-medscimonit-25-2419){ref-type="table"}[](#t5-medscimonit-25-2419){ref-type="table"}--[6](#t6-medscimonit-25-2419){ref-type="table"}.

CC genotype of rs2295281 indicated risk for TAD
-----------------------------------------------

We found that rs2295281 was strongly correlated with TAD risk based on dominant genetic model, which indicated that the CC genotype was a risk factor for TAD (TT+CT versus CC, OR=0.540, 95% CI \[0.320--0.911\], *P*=0.021) and that TT genotype and CT genotype of rs2295281 had a lower risk for TAD. For the subgroup analysis, there was no correlation between this polymorphism and TAD risk in either the hypertension subgroup or the normotensive group.

GG genotype of rs2236058 was a protective factor against TAD
------------------------------------------------------------

We found that rs2236058 was strongly correlated with the risk of TAD under the recessive genetic model, which indicated that the GG genotype was a protective factor against TAD (GG versus (CG+CC), OR=0.545, 95% CI \[0.351--0.845\], *P*=0.007) and that CG genotype and CC genotype of rs2236058 had an elevated risk for TAD. Hypertension-based subgroup analysis showed that rs2236058 was linked to the risk of TAD in the recessive genetic model and the homozygous model in the normotensive subgroup (GG versus (CG+CC), OR=0.298, 95% CI \[0.112--0.792\], *P*=0.015; GG versus CC, OR=0.528, 95% CI \[0.302--0.925\], *P*=0.026). However, rs2236058 was not found to be associated with TAD in the hypertension group. These findings implied that the rs2236058 polymorphism might influence the occurrence of TAD independently of hypertension.

The rs2336384 polymorphism was not correlated with TAD
------------------------------------------------------

We found that rs2336384 was neither correlated to the risk of TAD in the hypertension patient subgroup nor in the non-hypertension participant subgroup.

Association between rs3766741 polymorphism and TAD
--------------------------------------------------

Since there were only 2 participants carrying genotype GG in each group, we explored rs3766741 in the dominant genetic model only and found that it was not correlated with the risk of TAD (OR=0.443, 95% CI \[0.062--3.167\], *P*=0.405), either in the hypertension subgroup or in the normotensive subgroup.

Discussion
==========

The analysis of tagging SNPs is an important method for comprehensive detection of susceptibility genes associated with disease progression. In our study, we used the Haploview software to identify 5 tagging SNPs in Mfn2, which were subjected to genotyping. Based on univariate analysis, genotype distribution of rs2295281 in the hypertension subgroup was strongly linked to TAD risk (*P*=0.046). Logistic regression analysis revealed that rs2295281 was strongly correlated with the risk of TAD under the dominant genetic model, which indicated that genotype CC is a risk factor for TAD and that T allele carriers have a lower risk for TAD.

This project is the first genetic study on the correlation between Mfn2 and TAD using SNPs. Although there have not been any investigations on the correlation between Mfn2 and TAD, there are several studies on Mfn2 and hypertension. According to our analysis, 3 groups investigated the correlation between polymorphisms of Mfn2 and essential hypertension. Wang et al. \[[@b11-medscimonit-25-2419]\] investigated the association between 7 SNPs in intron 2 and essential hypertension and revealed that rs2236055, rs4846085, rs1474868, rs2336384, and rs873457 were strongly correlated with essential hypertension in a Chinese population. Later on, Wang et al. \[[@b12-medscimonit-25-2419]\] investigated the SNPs in the 5′-untranslated region (UTR) of Mfn2 and found a correlation between the −1248A\>G variant in the MFN-2 gene and hypertension in a Chinese population. These outcomes suggest that Mfn2 polymorphisms participate in the initiation of hypertension. In another study, Li et al. \[[@b13-medscimonit-25-2419]\] investigated the relationship between the tagging SNPs in Mfn2 and the risk of hypertension. Consistent with Wang et al. \[[@b11-medscimonit-25-2419]\] findings, they found that the rs2336384 polymorphism was strongly correlated with essential hypertension in a northern Han Chinese population. In addition, rs3766741, rs2236058, and rs2236057 polymorphisms were strongly correlated with essential hypertension. Despite the fact that the SNPs investigated in previous studies were different from those of this study, the outcomes imply that Mfn2 polymorphisms are correlated with essential hypertension risk.

Essential hypertension is the main pathogenic factor in TAD, and many of the gene polymorphisms associated with essential hypertension are also associated with TAD, such as MTHFR 677C/T and MMP9. Therefore, we inferred that Mfn2 may be correlated with the risk of TAD. Recently, several research groups have investigated the Mfn2 gene and may present evidence for the relationship between Mfn2 and TAD. Furthermore, other reports show that Mfn2 modulates endoplasmic reticulum stress, insulin resistance, and proliferation of VSMCs \[[@b18-medscimonit-25-2419]--[@b21-medscimonit-25-2419]\]. In addition, hypertension can cause hemodynamic changes in the aortic cavity, triggering stress response in the vessel wall. It also contributes to the weakness and destruction of the aortic wall. We speculate that hypertension is an independent determinant of TAD for the following reasons: 1) Mfn2 not only exists in the outer membrane of mitochondria but also modulates mitochondrial fusion and exists in the endoplasmic reticulum, regulating endoplasmic reticulum morphology \[[@b19-medscimonit-25-2419]\]. 2) Some *in vitro* experiments showed that Mfn2 knockout in fibroblasts in embryonic mice could increase the stress effect of the endoplasmic reticulum and accelerate apoptosis of the endoplasmic reticulum \[[@b21-medscimonit-25-2419]\], the medial degeneration leading to bands of cellular loss in the aortic media. Other oxidative factors produced by mitochondria are thought to lead to atherosclerosis and hypertension \[[@b22-medscimonit-25-2419]\]. 3) Insulin resistance modulates other atherosclerotic conditions, including hypertension, via stimulating protein kinase C (PKC) and advanced glycation end-products (AGEs)-RAGE axis leading to accumulation of AGEs.

Our study also indicated that rs2236058 was strongly correlated with the risk of TAD under the recessive genetic model, indicating that the GG genotype was a protective factor in TAD (GG versus (CG+CC), OR=0.545, 95% CI \[0.351--0.845\], *P*=0.007). CG genotype and CC genotype of rs2236058 are more susceptible to TAD. In addition, rs2236058 was strongly correlated with the risk of TAD in the recessive genetic model and homozygous model in the normotensive subgroup (GG versus (CG+CC), OR=0.298, 95% CI \[0.112--0.792\], *P*=0.015; GG versus CC, OR=0.528, 95% CI \[0.302--0.925\], *P*=0.026) but not in the hypertension subgroup. Interestingly, some patients with TAD have no history of hypertension. In *in vitro* experiments, the overexpression of Mfn2 significantly inhibited the proliferation of serum-activated VSMCs, which inhibited the cell cycle by inhibiting the ERK/MAPK pathway \[[@b18-medscimonit-25-2419],[@b19-medscimonit-25-2419],[@b23-medscimonit-25-2419]\]. This inhibition may cause the dysfunction of VSMCs, leading to the remodeling of the vessel wall. The vessel wall will then become progressively thinner, which is the pathological basis for the formation of TAD. This hypothesis may explain the relationship between Mfn2 and TAD.

All participants belonged to the ethnic Han population so as to minimize population stratification. Moreover, we excluded individuals with Ehlers-Danlos, Loeys-Dietz, and Marfan syndromes, and other genetic defect syndromes with the aim of avoiding selection bias. Nevertheless, there were some limitations to this study that should be mentioned. First, the data presented here should be interpreted with the understanding that the prognostic data obtained during the follow-up period was not sufficient to enable assessment of the relationship between the polymorphisms and TAD, which may limit or underrepresent the role of Mfn2 polymorphisms in the occurrence of hypertension. Second, this study only focused on 5 of the most common tagging SNPs, but other SNPs, such as low frequency SNPs, were not examined. Additional studies should determine the mechanisms that orchestrate the effects of the positive SNPs on the functions of Mfn2 in the pathogenesis of TAD.

Conclusions
===========

We showed that rs2295281 and rs2236058 in Mfn2 were strongly correlated with TAD in a Han Chinese population. These results provide a clue for the mechanism underlying TAD, and additional large sample, functional studies on Mfn2 in TAD are needed to verify the exact mechanisms. These findings should additionally be tested in different populations worldwide.
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###### 

Characteristics of Controls and TAD.

  Variables              Controls (n=451)   TAD (n=200)    *P*-value
  ---------------------- ------------------ -------------- -----------
  Age (years)            47.94±5.54         47.33±10.81    0.448
  Gender (Male/Female)   278/173            155/45         \<0.001
  SBP (mmHg)             124.17±17.15       139.22±26.04   \<0.001
  DBP (mmHg)             80.44±13.93        81.43±17.79    0.485
  BMI (kg/m^2^)          25.82±5.81         25.35±3.74     0.297
  CREA (mmol/L)          74.39±12.24        93.95±18.37    \<0.001
  UREA (mmol/L)          5.19±1.33          6.76±3.55      \<0.001
  TCHO (mmol/L)          5.10±0.89          4.22±0.98      \<0.001
  TG (mmol/L)            1.72±0.34          1.75±0.99      0.715
  LDL-C (mmol/L)         3.18±0.81          2.81±0.79      \<0.001
  HDL-C (mmol/L)         1.22±0.48          0.90±0.26      \<0.001
  Hypertension (n, %)    205 (45.5%)        149 (74.5%)    \<0.001
  Smokers (n,%)          152 (33.9%)        96 (48.0%)     0.001
  Drinkers (n, %)        227 (50.6%)        43 (21.5%)     \<0.001

Continuous variables were expressed as means ± standard deviations when normally distributed and as median (interquartile range) when asymmetrically distributed. BMI -- body mass index; CREA -- creatinine; DBP -- diastolic blood pressure; EH -- essential hypertensive patients; HDL-C -- high-density lipoprotein; HR -- heart rate; LDL-C -- low-density lipoprotein; NT -- normotensive subjects; SBP -- systolic blood pressure; TCHO -- total cholesterol; TG -- triglyceride; UREA -- urea nitrogen.

###### 

Genotype distribution of Mfn2 in case and control group.

  SNP                                      Genotype (frequency, %)   χ^2^         *P*-value            
  -------------- ------------ ------------ ------------------------- ------------ ------------ ------- -------
                                           **GG**                    **GT**       **TT**               
  rs2336384      Total        Case         38 (19.0)                 111 (55.5)   51 (25.5)    4.724   0.094
  Control        89 (20.1)    207 (46.8)   146 (33.1)                                                  
  Hypertension   Case         24 (16.1)    86 (57.7)                 39 (26.2)    3.628        0.163   
  Control        42 (21.0)    95 (47.5)    63 (31.5)                                                   
  Normotension   Case         13 (26.0)    25 (50.0)                 12 (24.0)    2.346        0.310   
  Control        47 (19.4)    112 (46.3)   83 (34.3)                                                   
                                           **TT**                    **CT**       **CC**               
  rs2295281      Total        Case         20 (10.0)                 112 (56.0)   68 (34.0)    8.479   0.014
  Control        77 (16.9)    204 (45.2)   170 (37.9)                                                  
  Hypertension   Case         15 (10.1)    86 (57.7)                 49 (32.2)    6.131        0.046   
  Control        27 (13.2)    91 (44.4)    87 (42.4)                                                   
  Normotension   Case         5 (10.0)     26 (52.0)                 19 (38.0)    2.929        0.231   
  Control        50 (20.3)    113 (45.9)   83 (33.8)                                                   
                                           **GG**                    **AG**       **AA**               
  rs1703756      Total        Case         2 (1.0)                   47 (23.5)    151 (57.5)   3.499   0.174
  Control        10 (2.2)     81 (18.1)    357 (79.7)                                                  
  Hypertension   Case         1 (0.7)      33 (22.1)                 115 (77.2)   3.820        0.148   
  Control        7 (3.4)      36 (17.7)    161 (78.9)                                                  
  Normotension   Case         1 (2.0)      13 (26.0)                 36 (72.0)    1.747        0.417   
  Control        3 (1.2)      45 (18.4)    196 (80.4)                                                  
                                           **GG**                    **CG**       **CC**               
  rs2236058      Total        Case         32 (16.0)                 123 (61.5)   45 (22.5)    14.38   0.001
  Control        118 (26.6)   204 (46.1)   121 (27.3)                                                  
  Hypertension   Case         27 (18.1)    92 (61.1)                 31 (20.8)    5.696        0.058   
  Control        43 (21.7)    96 (48.5)    59 (29.8)                                                   
  Normotension   Case         5 (10.0)     31 (62.0)                 14 (28.0)    9.985        0.007   
  Control        75 (30.6)    108 (44.1)   62 (25.3)                                                   
                                           **CC**                    **CG**       **GG**               
  rs3766741      Total        Case         166 (83.0)                32 (16.0)    2 (1.0)      1.446   0.485
  Control        362 (80.6)   85 (18.9)    2 (0.5)                                                     
  Hypertension   Case         124 (83.2)   23 (15.5)                 2 (1.3)      1.961        0.375   
  Control        161 (79.3)   41 (20.2)    1 (0.5)                                                     
  Normotension   Case         41 (82.0)    9 (18.0)                  0 (0)        0.204        0.903   
  Control        201 (80.7)   44 (17.9)    1 (0.4)                                                     

###### 

Allele frequency of MFN-2 in case and control group.

  SNP                                      Allele (frequency, %)   χ^2^          *P*-value   
  -------------- ------------ ------------ ----------------------- ------------- ----------- -------
                                           **G**                   **T**                     
  rs2336384      Total        Case         187 (46.75)             213 (53.25)   1.14        0.286
  Control        385 (43.6)   499 (56.4)                                                     
  Hypertension   Case         134 (44.9)   164 (55.1)              0.003         0.955       
  Control        179 (44.8)   221 (55.2)                                                     
  Normotension   Case         51 (26.0)    49 (50.0)               3.501         0.061       
  Control        206 (40.9)   298 (59.1)                                                     
                                           **T**                   **C**                     
  rs2295281      Total        Case         152 (38.0)              248 (62.0)    0.27        0.601
  Control        355 (39.5)   543 (60.5)                                                     
  Hypertension   Case         116 (38.7)   184 (61.3)              0.812         0.368       
  Control        145 (35.4)   265 (64.6)                                                     
  Normotension   Case         36 (36.0)    64 (64.0)               1.814         0.178       
  Control        21 (43.3)    27 (56.7)                                                      
                                           **G**                   **A**                     
  rs1703756      Total        Case         51 (12.75)              349 (7.25)    0.58        0.445
  Control        101 (11.3)   795 (88.7)                                                     
  Hypertension   Case         35 (11.7)    263 (88.3)              0.042         0.837       
  Control        50 (12.3)    358 (87.7)                                                     
  Normotension   Case         15 (15.0)    85 (85.0)               1.724         0.189       
  Control        51 (10.5)    43989.5)                                                       
                                           **G**                   **C**                     
  rs2236058      Total        Case         186 (46.8)              212 (53.2)    0.942       0.332
  Control        440 (49.7)   446 (50.3)                                                     
  Hypertension   Case         145 (48.7)   153 (51.3)              0.497         0.481       
  Control        182 (45.9)   214 (54.1)                                                     
  Normotension   Case         41 (42.0)    59 (58.0)               4.512         0.034       
  Control        25 (52.7)    23 (47.3)                                                      
                                           **C**                   **G**                     
  rs3766741      Total        Case         364 (91.0)              36 (9.0)      0.26        0.607
  Control        809 (90.1)   89 (9.9)                                                       
  Hypertension   Case         271 (90.9)   27 (9.1)                0.450         0.502       
  Control        363 (89.4)   43 (10.6)                                                      
  Normotension   Case         91 (91.0)    9 (9.0)                 0.012         0.913       
  Control        44 (90.7)    46 (9.3)                                                       

###### 

Logistic regression to correct the association of MFN-2 gene polymorphisms with TAD.

  SNP          Models             Genotype               OR (95%CI)^a^          *P^a^*
  ------------ ------------------ ---------------------- ---------------------- --------
  rs2336384    Additive           GG *vs*. GT *vs*. TT   0.876 (0.687--1.117)   0.287
  Dominant     (GG+GT) *vs*. TT   1.045 (0.679--1.607)   0.842                  
  Recessive    GG *vs*. (GT+TT)   0.707 (0.483--1.034)   0.074                  
  Homozygote   GG *vs*. TT        0.818 (0.498--1.343)   0.427                  
  rs2295281    Additive           TT *vs*. CT *vs*. CC   0.930 (0.728--1.187)   0.561
  Dominant     (TT+CT) *vs*. CC   0.540 (0.320--0.911)   0.021                  
  Recessive    TT *vs*. (CT+CC)   1.198 (0.839--1.709)   0.320                  
  Homozygote   TT *vs*. CC        0.649 (0.368--1.144)   0.134                  
  rs17037564   Additive           GG *vs*. AG *vs*. AA   1.143 (0.804--1.625)   0.456
  Dominant     (GG+AG) *vs*. AA   0.565 (0.119--2.686)   0.473                  
  Recessive    GG *vs*. (AG+AA)   1.238 (0.826--1.857)   0.301                  
  Homozygote   GG *vs*. AA        0.473 (0.102--2.184)   0.327                  
  rs2236058    Additive           GG *vs*. CG *vs*. CC   0.906 (0.709--1.156)   0.426
  Dominant     (GG+CG) *vs*. CC   1.317 (0.884--1.963)   0.176                  
  Recessive    GG *vs*. (CG+CC)   0.545 (0.351--0.845)   0.007                  
  Homozygote   GG *vs*. CC        0.861 (0.662--1.119)   0.861                  
  rs3766741    Dominant           (CG+GG) *vs*. CC       0.443 (0.062--3.167)   0.405

###### 

Logistic regression to correct the association of MFN-2 gene polymorphisms with TAD in normotensive group.

  SNP          Models             Genotype               OR (95%CI)^a^          *P^a^*
  ------------ ------------------ ---------------------- ---------------------- --------
  rs2336384    Additive           GG *vs*. GT *vs*. TT   0.678 (0.434--1.061)   0.089
  Dominant     (GG+GT) *vs*. TT   0.563 (0.269--1.178)   0.127                  
  Recessive    GG *vs*. (GT+TT)   0.625 (0.298--1.308)   0.212                  
  Homozygote   GG *vs*. TT        0.689 (0.440--1.080)   0.104                  
  rs2295281    Additive           TT *vs*. CT *vs*. CC   0.750 (0.470--1.197)   0.228
  Dominant     (TT+CT) *vs*. CC   0.472 (0.172--1.298)   0.146                  
  Recessive    TT *vs*. (CT+CC)   0.815 (0.422--1.575)   0.543                  
  Homozygote   TT *vs*. CC        0.670 (0.390--1.151)   0.147                  
  rs17037564   Additive           GG *vs*. AG *vs*. AA   1.361 (0.697--2.657)   0.367
  Dominant     (GG+AG) *vs*. AA   2.633 (0.228--3.408)   0.438                  
  Recessive    GG *vs*. (AG+AA)   1.335 (0.642--2.779)   0.439                  
  Homozygote   GG *vs*. AA        1.684 (0.494--5.739)   0.404                  
  rs2236058    Additive           GG *vs*. CG *vs*. CC   0.663 (0.432--1.017)   0.060
  Dominant     (GG+CG) *vs*. CC   0.826 (0.451--1.902)   0.835                  
  Recessive    GG *vs*. (CG+CC)   0.298 (0.112--0.792)   0.015                  
  Homozygote   GG *vs*. CC        0.528 (0.302--0.925)   0.026                  
  rs3766741    Dominant           (CG+GG) *vs*. CC       0.996 (0.998--1.004)   0.652

###### 

Logistic regression to correct the association of MFN-2 gene polymorphisms with TAD in hypertensive group.

  SNP          Models             Genotype               OR (95%CI)^a^          *P^a^*
  ------------ ------------------ ---------------------- ---------------------- --------
  rs2336384    Additive           GG *vs*. GT *vs*. TT   0.983 (0.716--1.350)   0.914
  Dominant     (GG+GT) *vs*. TT   0.781 (0.482--1.265)   0.315                  
  Recessive    GG *vs*. (GT+TT)   1.328 (0.754--2.341)   0.326                  
  Homozygote   GG *vs*. TT        1.017 (0.731--1.416)   0.921                  
  rs2295281    Additive           TT *vs*. CT *vs*. CC   1.204 (0.865--1.677)   0.272
  Dominant     (TT+CT) *vs*. CC   0.820 (0.412--1.632)   0.572                  
  Recessive    TT *vs*. (CT+CC)   1.532 (0.975--2.408)   0.064                  
  Homozygote   TT *vs*. CC        1.038 (0.718--1.501)   0.843                  
  rs17037564   Additive           GG *vs*. AG *vs*. AA   0.974 (0.616--1.542)   0.912
  Dominant     (GG+AG) *vs*. AA   0.235 (0.028--1.873)   0.183                  
  Recessive    GG *vs*. (AG+AA)   1.107 (0.655--1.873)   0.703                  
  Homozygote   GG *vs*. AA        0.495 (0.171--1.436)   0.196                  
  rs2236058    Additive           GG *vs*. CG *vs*. CC   1.141 (0.826--1.578)   0.424
  Dominant     (GG+CG) *vs*. CC   1.647 (0.986--2.752)   0.057                  
  Recessive    GG *vs*. (CG+CC)   0.813 (0.470--1.409)   0.461                  
  Homozygote   GG *vs*. CC        1.072 (0.766--1.500)   0.685                  
  rs3766741    Dominant           (CG+GG) *vs*. CC       0.418 (0.037--4.690)   0.479
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